F-group (family)
5054.1.1.58 YVC1_C
Ligands and drugs
1,016
Member domains
718
with ligand contacts (≤ 4 Å)
70.7% of members
231
with DrugDomain annotations
22.7% of members
78
with a DrugBank compound
7.7% of members
Aggregated over all current member domains of this group. Drug annotations come from DrugDomain; buffers and crystallization additives are excluded from the tables below.
Chemical profile
Chemical profiles are computed for X-groups. 5054.1.1.58 belongs to X-group 5054 Voltage-gated ion channels, which binds 10.4 ligand superclasses per 20 proteins, broader than 97% of the 256 X-groups with enough proteins to compare. View its chemical profile →
DrugBank compounds
| DrugBank | PDB ligand | Name | Domains |
|---|---|---|---|
| DB06515 | 6EU | Resiniferatoxin | 31 |
| DB09061 | P0T | Cannabidiol | 22 |
| DB04540 | CLR | Cholesterol | 13 |
| DB00141 | NAG | N-Acetylglucosamine | 4 |
| DB06774 | 4DY | Capsaicin | 4 |
| DB16033 | XPW | GSK2798745 | 4 |
| DB00825 | — | — | 2 |
| DB01744 | — | Camphor | 2 |
| DB11345 | — | — | 2 |
| DB14011 | — | — | 2 |
| DB09086 | — | Eugenol | 1 |
| DB11755 | — | Tetrahydrocannabivarin | 1 |
| DB14123 | — | — | 1 |
Most frequently bound compounds
| PDB ligand | Name | Domains in contact |
|---|---|---|
| NAmetal | SODIUM ION | 203 |
| POV | (2S)-3-(hexadecanoyloxy)-2-[(9Z)-octadec-9-enoyloxy]propyl 2-(trimethylammonio)ethyl phosphate | 144 |
| CLR | CHOLESTEROL | 116 |
| 6EU | resiniferatoxin | 103 |
| Y01 | CHOLESTEROL HEMISUCCINATE | 101 |
| CAmetal | CALCIUM ION | 74 |
| 6OU | [(2~{R})-1-[2-azanylethoxy(oxidanyl)phosphoryl]oxy-3-hexadecanoyloxy-propan-2-yl] (~{Z})-octadec-9-enoate | 70 |
| LBN | 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine | 48 |
| XJ7 | (2S)-1-(butanoyloxy)-3-{[(R)-hydroxy{[(1r,2R,3S,4S,5R,6S)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl]oxy}propan-2-yl tridecanoate | 42 |
| DU0 | 2-[2-[(1~{S},2~{S},4~{S},5'~{R},6~{R},7~{S},8~{R},9~{S},12~{S},13~{R},16~{S})-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icos-18-ene-6,2'-oxane]-16-yl]oxyethyl]propane-1,3-diol | 40 |
| FZ4 | 2-aminoethyl diphenylborinate | 32 |
| PEX | 1,2-DIDECANOYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE | 32 |
| YUV | (25R)-14beta,17beta-spirost-5-en-3beta-ol | 28 |
| YUY | (2R)-2-(hydroxymethyl)-4-{[(25R)-10alpha,14beta,17beta-spirost-5-en-3beta-yl]oxy}butyl 4-O-alpha-D-glucopyranosyl-beta-D-glucopyranoside | 28 |
| 8IJ | (2R)-3-{[(R)-hydroxy{[(1S,2R,3R,4S,5S,6R)-2,3,4,5,6-pentahydroxycyclohexyl]oxy}phosphoryl]oxy}propane-1,2-diyl dioctadecanoate | 27 |
| 4DY | (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide | 20 |
| 6IY | (10R,13S)-16-amino-13-hydroxy-7,13-dioxo-8,12,14-trioxa-13lambda~5~-phosphahexadecan-10-yl hexadecanoate | 20 |
| 98R | [(2S)-2-[(E)-octadec-10-enoyl]oxy-3-oxidanyl-propyl] octadec-10-enoate | 20 |
| P0T | cannabidiol | 20 |
| PIO | [(2R)-2-octanoyloxy-3-[oxidanyl-[(1R,2R,3S,4R,5R,6S)-2,3,6-tris(oxidanyl)-4,5-diphosphonooxy-cyclohexyl]oxy-phosphoryl]oxy-propyl] octanoate | 20 |